Significant Agreements - Neurocrine Collaboration Agreements (Details) $ / shares in Units, $ in Thousands				1 Months Ended						3 Months Ended				12 Months Ended
	Mar. 01, 2023 item	Jan. 08, 2023 USD ($) $ / shares shares	Mar. 04, 2022 USD ($) item	Oct. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($) item Program $ / shares shares	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($) Program $ / shares shares	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2024 USD ($) item shares	Dec. 31, 2023 USD ($) item	Dec. 31, 2022 USD ($)	Jun. 30, 2024 USD ($)	Apr. 30, 2024 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue														$ 80,001	$ 250,008	$ 40,907
Contract with customer liability revenue recognized														0	0	$ 40,000
Contract with Customer, Liability, Noncurrent											$ 32,359			6,003	32,359
Contract with Customer, Asset, Net, Current											3,341			676	3,341
Allocation of Transaction Price
Contract with Customer, Liability, Current											42,881			24,394	42,881
Option and License Agreement | Novartis Pharma, AG
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue				$ 15,000										15,000
Contract with customer liability revenue recognized														15,000	79,000
Allocation of transaction price			$ 18,000								25,000				$ 25,000
Number of targets | item	2		2
Upfront payment			$ 54,000											15,000
Option and License Agreement | Novartis Pharma, AG | Sales milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner			$ 175,000
2019 Neurocrine Collaborative Agreement | FA Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of profit or loss under co-co option									40.00%
2019 Neurocrine Collaborative Agreement | Neurocrine
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments						$ 5,000
Deferred revenue														$ 2,800
Allocation of transaction price						5,000
Number of collaboration programs | item														3
Number of discovery programs									2						97,382
Issuance of common stock, shares | shares									4,179,728					4,179,728
Upfront payment									$ 115,000					$ 115,000
Price per share | $ / shares									$ 11.9625
Stock Issued During Period, Value, New Issues									$ 50,000					5,000
Aggregate maximum milestone payments to be received from collaborative partner									$ 130,000
Estimated cost reimbursement											83,300	$ 81,700	$ 80,000	431,100
Termination period									10 years
Discount related to equity investment														27,600
Equity investment														50,000
Allocation of Transaction Price
Allocation of variable consideration														82,370
Allocation of fixed consideration														92,400
Cumulative catch up of revenue recognized						4,400
Milestone payment to be received						$ 5,000
Reimbursement costs expected to be received														400
Consideration received								$ 5,000
2019 Neurocrine Collaborative Agreement | Neurocrine | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of reduction in royalty payments									50.00%
2019 Neurocrine Collaborative Agreement | Neurocrine | VY-AADC
Allocation of Transaction Price
Allocation of variable consideration														53,863
Allocation of fixed consideration											49,045				$ 49,045
2019 Neurocrine Collaborative Agreement | Neurocrine | FA Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of profit or loss under co-co option									60.00%
Allocation of Transaction Price
Allocation of variable consideration														19,560
Allocation of fixed consideration											25,647				25,647
2019 Neurocrine Collaborative Agreement | Neurocrine | Discovery program 1
Allocation of Transaction Price
Allocation of variable consideration														4,546
Allocation of fixed consideration											14,443				14,443
2019 Neurocrine Collaborative Agreement | Neurocrine | Discovery program 2
Allocation of Transaction Price
Allocation of variable consideration														4,401
Allocation of fixed consideration											8,247				8,247
2019 Neurocrine Collaborative Agreement | Neurocrine | Active programs
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer liability revenue recognized														$ 10,400	9,800
2019 Neurocrine Collaborative Agreement | Neurocrine | Development and regulatory milestones | FA Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner									$ 195,000
2019 Neurocrine Collaborative Agreement | Neurocrine | Commercial milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Per milestone, maximum milestone payments to be received from collaborative partner									275,000
Aggregate maximum milestone payments to be received from collaborative partner									$ 1,100,000
2023 Neurocrine Collaborative Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of profit or loss under co-co option		50.00%
Percentage of development costs incurred		50.00%
Stock Issued During Period, Value, New Issues															31,121
2023 Neurocrine Collaborative Agreement | Development milestone | Minimum
Allocation of Transaction Price
Number of countries received regulatory approval | item														1
2023 Neurocrine Collaborative Agreement | Neurocrine
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments					$ 3,000		$ 3,000
Allocation of transaction price					$ 3,000					$ 3,000
Number of discovery programs | item														3
Number of development and commercialization licenses | item														2
Contract with Customer, Liability, Noncurrent											30,700			$ 5,300	30,700
Contract with Customer, Asset, Net, Current											1,800			300	1,800
Issuance of common stock, shares | shares		4,395,588					4,395,588
Amount of premium							$ 7,900
Percentage of profit or loss under co-co option		50.00%
Percentage of development costs incurred		50.00%
Upfront payment							$ 136,000
Price per share | $ / shares		$ 8.88					$ 8.88
Stock Issued During Period, Value, New Issues		$ 39,000					$ 39,000
Termination period							10 years
Discount related to equity investment							$ 39,000
Allocation of Transaction Price
Allocation of variable consideration														8,984
Allocation of fixed consideration							$ 143,900							149,880
Cumulative catch up of revenue recognized										$ 2,000				27,600	69,100
Milestone payment to be received																	$ 3,000	$ 3,000
Reimbursement costs expected to be received														9,000
Costs to obtain collaboration agreement											400				400
Contract with Customer, Liability, Current											$ 38,400			22,300	38,400
2023 Neurocrine Collaborative Agreement | Neurocrine | GBA1
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer liability revenue recognized														3,000	69,500
Allocation of Transaction Price
Allocation of variable consideration														7,960
Allocation of fixed consideration														72,459
2023 Neurocrine Collaborative Agreement | Neurocrine | Discovery program 1
Allocation of Transaction Price
Allocation of variable consideration														363
Allocation of fixed consideration														27,807
2023 Neurocrine Collaborative Agreement | Neurocrine | Discovery program 2
Allocation of Transaction Price
Allocation of variable consideration														356
Allocation of fixed consideration														24,807
2023 Neurocrine Collaborative Agreement | Neurocrine | Discovery program 3
Allocation of Transaction Price
Allocation of variable consideration														305
Allocation of fixed consideration														24,807
2023 Neurocrine Collaborative Agreement | Neurocrine | Discovery Programs 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer liability revenue recognized														$ 44,500	$ 5,500
Number of discovery programs | item														3	3
2023 Neurocrine Collaborative Agreement | Neurocrine | Development milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Discovery programs under development | Program							3
2023 Neurocrine Collaborative Agreement | Neurocrine | Development milestone | GBA1
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner							$ 985,000
2023 Neurocrine Collaborative Agreement | Neurocrine | Development milestone | Discovery Programs 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner							175,000
2023 Neurocrine Collaborative Agreement | Neurocrine | Commercial milestone | GBA1 | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Per milestone, maximum milestone payments to be received from collaborative partner							$ 950,000
Allocation of Transaction Price
Number of products | item							2
2023 Neurocrine Collaborative Agreement | Neurocrine | Commercial milestone | Discovery Programs 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Per milestone, maximum milestone payments to be received from collaborative partner							$ 275,000
Allocation of Transaction Price
Number of products | item							1
2023 Neurocrine Collaborative Agreement | Neurocrine | Research and development milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer liability revenue recognized														$ 2,200
2023 Neurocrine Collaborative Agreement | Neurocrine | Research and development milestone | GBA1
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer liability revenue recognized															$ 5,800